/ 2 items

#KYMR↓

Featured/ DSGN/ 03/16/2026 · 12:42 PM

Jefferies Goes All-In on Biotech: 5 Buy-Rated Stocks Poised for Big 2026 Catalysts

Jefferies initiates Buy on Design Therapeutics ($15 PT) & assumes coverage on Revolution Medicines ($140), Kymera ($110), Immatics ($18), Insmed ($228).

KYMR/ 12/08/2025 · 11:09 AM

Kymera Stock Soars on Breakthrough Eczema Drug Results

Kymera Therapeutics (KYMR) shares surge after Phase 1b trial shows KT-621 oral pill achieves Dupixent-like efficacy in treating moderate to severe eczema with favorable safety profile.